亚马逊原住民重度抑郁症的药物基因组学研究
本研究对64名亚马逊原住民进行全外显子测序,分析9个与抗抑郁药代谢及反应相关的基因,共鉴定125个变异,其中6个可能为新变异,至少9个变异频率与其他人群存在显著差异,提示该人群具有独特遗传背景,为未来药物基因组学生物标志物研究提供基础。
要点
- 巴西亚马逊原住民在HTR2A、HTR2C、CYP2D6、CYP1A2等基因上存在独特变异谱。
- 至少9个变异频率与原住民以外人群存在显著差异。
- 研究未评估临床药物反应,尚不能直接指导剂量调整。
核心结论
- 巴西亚马逊原住民具有独特的药物基因组变异谱,可能影响抗抑郁药代谢与反应。
研究设计与样本
- 对64名亚马逊原住民进行全外显子测序,分析9个与药物处置及药效相关的基因。
- 使用Fisher精确检验在RStudio v.3.5.1中比较原住民与其他世界人群的等位基因频率。
主要发现
- 共鉴定125个变异,其中6个在HTR2A、HTR2C、CYP2D6和CYP1A2基因上可能为新变异。
- 至少9个变异在原住民与其他世界人群间显示显著频率差异。
临床怎么用
- 目前尚不能据此调整抗抑郁药剂量,但可为未来原住民药物基因组学生物标志物研究提供候选变异。
局限性
- 本研究未评估临床药物反应,无法直接推断变异与抗抑郁药疗效的关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Major depressive disorder is a highly prevalent psychological disorder worldwide and its main treatment is the use of Selective Serotonin Reuptake Inhibitors. However, few studies have demonstrated the relationship between the presence of genetic variants in pharmacogenes and the efficacy of these drugs, especially in populations with a unique genetic profile, such as the Indigenous peoples of the Amazon. Our study characterized the molecular profile of nine genes related to drug administration, metabolization, distribution, and elimination pathways and pharmacodynamic mechanisms of drug response through Whole Exome Sequencing applied in 64 Indigenous located in the Amazon. We compared the allele frequencies of the variants in Indigenous peoples and other world populations using Fisher's exact test carried out in RStudio v.3.5.1. We identified a total of 125 variants, of which 6 are possible new variants in our population on the HTR2A, HTR2C, CYP2D6, and CYP1A2 genes. At least 9 variants showed a significant difference in the Indigenous population compared with other populations worldwide. Our study reaffirms the unique genetic profile of the Brazilian Amazon Indigenous population and allows us to contribute population-specific variants that may serve as future pharmacogenomic biomarkers that help in the understanding of the individual genetic profiles of Indigenous people. Although the present study does not evaluate clinical drug response, the characterization of these variants provides a foundation for future studies exploring their potential impact on antidepressant efficacy in Indigenous populations and the application of this knowledge in the development of specific treatment protocols guided by pharmacogenomics.
引用
- Aguiar KEC, da Silva NM, Rodrigues JCG, et al. Pharmacogenomics of Major Depressive Disorder in Indigenous Amazonian Populations. Clin Pharmacol Ther. 2026. PMID: 41542984. doi:10.1002/cpt.70207
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。